Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Tiotropium + Olodaterol FDC in Chinese COPD Patients
NCT02969317Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration Time Curve of Olodaterol in Plasma Over the Time Interval From 0 to 6 Hours After Drug Administration, Time From Dosing to the Maximum Concentration of Olodaterol in Plasma at Day 20 and 18 more. Started Feb 2017; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02969317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969317.